Tanshinone IIA alleviates cardiac hypertrophy through m6A modification of galectin-3

References

• Oldfield CJ, Duhamel TA, Dhalla NS. Mechanisms for the transition from physiological to pathological cardiac hypertrophy. Can J Physiol Pharmacol. 2020;98(2):74–84.
   PubMed Web of Science ®Google Scholar
• Lyon RC, Zanella F, Omens JH, et al. Mechanotransduction in cardiac hypertrophy and failure. Circ Res. 2015;116(8):1462–1476.
   PubMed Web of Science ®Google Scholar
• Yuan M, Zhao B, Jia H, et al. Sinomenine ameliorates cardiac hypertrophy by activating Nrf2/ARE signaling pathway. Bioengineered. 2021;12(2):12778–12788.
   PubMed Web of Science ®Google Scholar
• Facundo HDTF, Brainard RE, Caldas FRL, et al. Mitochondria and cardiac hypertrophy. Adv Exp Med Biol. 2017;982:203–226.
   PubMed Web of Science ®Google Scholar
• Zhu L, Li C, Liu Q, et al. Molecular biomarkers in cardiac hypertrophy. J Cell Mol Med. 2019;23(3):1671–1677.
   PubMed Web of Science ®Google Scholar
• Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89(9):1401–1438.
   PubMed Web of Science ®Google Scholar
• Liu W, Lin W, Yu L. Long non-coding RNA muscleblind like splicing regulator 1 antisense RNA 1 (LncRNA MBNL1-AS1) promotes the progression of acute myocardial infarction by regulating the microRNA-132-3p/SRY-related high-mobility-group box 4 (SOX4) axis. Bioengineered. 2022;13:1424–1435.
   PubMed Web of Science ®Google Scholar
• Shimizu I, Minamino T. Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245–262.
   PubMed Web of Science ®Google Scholar
• Huang H, Song C, Chang J. Synthesis and biological activity study of tanshinone derivatives: a literature and patent review. Curr Top Med Chem. 2020;20(28):2520–2534.
   PubMed Web of Science ®Google Scholar
• Shi MJ, Dong BS, Yang WN, et al. Preventive and therapeutic role of tanshinone IIA in hepatology. Biomed Pharmacother. 2019;112:108676.
   PubMed Web of Science ®Google Scholar
• Xu S, Liu P. Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 2013;23(2):149–153.
   PubMed Web of Science ®Google Scholar
• Gao S, Liu Z, Li H, et al. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 2012;220(1):3–10.
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu H. Anti-inflammatory and immunomodulatory mechanism of tanshinone IIA for atherosclerosis. Evid Based Complement Alternat Med. 2014;2014:267976.
   PubMedGoogle Scholar
• Feng J, Liu L, Yao F, et al. The protective effect of tanshinone IIa on endothelial cells: a generalist among clinical therapeutics. Expert Rev Clin Pharmacol. 2021;14(2):239–248.
   PubMed Web of Science ®Google Scholar
• Fang ZY, Zhang M, Liu JN, et al. Tanshinone IIA: a review of its anticancer effects. Front Pharmacol. 2021;11:611087.
   PubMed Web of Science ®Google Scholar
• Ying Q, Teng Y, Zhang J, et al. Therapeutic effect of tanshinone IIA on liver fibrosis and the possible mechanism: a preclinical meta-analysis. Evid Based Complement Alternat Med. 2019;2019:7514046.
   PubMed Web of Science ®Google Scholar
• Guo R, Li L, Su J, et al. Pharmacological activity and mechanism of tanshinone IIA in related diseases. Drug Des Devel Ther. 2020;14:4735–4748.
   PubMed Web of Science ®Google Scholar
• Zhang M, Cheng K, Chen H, et al. MicroRNA-27 attenuates pressure overload-induced cardiac hypertrophy and dysfunction by targeting galectin-3. Arch Biochem Biophys. 2020;689:108405.
   PubMed Web of Science ®Google Scholar
• Li Y, Shi Y, He Y, et al. RNA binding motif protein-38 regulates myocardial hypertrophy in LXR-α-dependent lipogenesis pathway. Bioengineered. 2021;12(2):9655–9667.
   PubMed Web of Science ®Google Scholar
• Tan X, Li J, Wang X, et al. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway. Int J Biol Sci. 2011;7(3):383–389.
   PubMed Web of Science ®Google Scholar
• Feng J, Chen HW, Pi LJ, et al. Protective effect of tanshinone IIA against cardiac hypertrophy in spontaneously hypertensive rats through inhibiting the Cys-C/Wnt signaling pathway. Oncotarget. 2017;8(6):10161–10170.
   PubMedGoogle Scholar
• Weng YS, Wang HF, Pai PY, et al. Tanshinone IIA prevents Leu27IGF-II-Induced cardiomyocyte hypertrophy mediated by estrogen receptor and subsequent akt activation. Am J Chin Med. 2015;43(8):1567–1591.
   PubMed Web of Science ®Google Scholar
• Chen YF, Day CH, Lee NH, et al. Tanshinone IIA inhibits β-catenin nuclear translocation and IGF-2R activation via estrogen receptors to suppress angiotensin II-induced H9c2 cardiomyoblast cell apoptosis. Int J Med Sci. 2017 Sept 30;14(12):1284–1291.
   PubMedGoogle Scholar
• de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11(9):811–817.
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhang L, Li L, et al. Galectin-3 mediates cardiac remodeling caused by impaired glucose and lipid metabolism through inhibiting two pathways of activating Akt. Am J Physiol Heart Circ Physiol. 2021;320(1):H364–H380.
   PubMed Web of Science ®Google Scholar
• Emet S, Dadashov M, Sonsoz MR, et al. Galectin-3: a novel biomarker predicts sudden cardiac death in hypertrophic cardiomyopathy. Am J Med Sci. 2018;356(6):537–543.
   PubMed Web of Science ®Google Scholar
• Frunza O, Russo I, Saxena A, et al. Myocardial galectin-3 expression is associated with remodeling of the pressure-overloaded heart and may delay the hypertrophic response without affecting survival, dysfunction, and cardiac fibrosis. Am J Pathol. 2016;186(5):1114–1127.
   PubMed Web of Science ®Google Scholar
• Qin Y, Li L, Luo E, et al. Role of m6A RNA methylation in cardiovascular disease (review). Int J Mol Med. 2020;46(6):1958–1972.
   PubMed Web of Science ®Google Scholar
• Dorn LE, Lasman L, Chen J, et al. The N6-Methyladenosine mRNA methylase METTL3 controls cardiac homeostasis and hypertrophy. Circulation. 2019;139(4):533–545.
   PubMed Web of Science ®Google Scholar
• Gao XQ, Zhang YH, Liu F, et al. The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N6-methyladenosine methylation of Parp10 mRNA. Nat Cell Biol. 2020;22(11):1319–1331.
   PubMedGoogle Scholar
• Tang Y, Chen K, Song B, et al. m6A-Atlas: a comprehensive knowledgebase for unraveling the N6-methyladenosine (m6A) epitranscriptome. Nucleic Acids Res. 2021;49(D1):D134–D143.
   PubMed Web of Science ®Google Scholar
• Zhang H, Shi X, Huang T, et al. Dynamic landscape and evolution of m6A methylation in human. Nucleic Acids Res. 2020;48(11):6251–6264.
   PubMed Web of Science ®Google Scholar
• Reichel M, Köster T, Staiger D. Marking RNA: m6A writers, readers, and functions in arabidopsis. J Mol Cell Biol. 2019;11(10):899–910.
   PubMed Web of Science ®Google Scholar